These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9467275)

  • 21. Malignant hyperthermia in a 3-month-old infant: a case report.
    Pennington GP; Joeris L
    J Med Assoc Ga; 1996 Sep; 85(3):162-3. PubMed ID: 8870451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anesthetic management of the King-Denborough syndrome].
    Iwatsubo T; Yoshikawa M; Karashima Y; Kurita N; Shimoda T; Takahashi H; Horiuchi T; Kitaguchi K; Furuya H
    Masui; 2001 Apr; 50(4):390-3. PubMed ID: 11345752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Malignant hyperthermia of Duchenne muscular dystrophy: application of clinical grading scale and caffeine contracture of skinned muscle fibers].
    Takagi A
    Rinsho Shinkeigaku; 2000 May; 40(5):423-7. PubMed ID: 11002722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.
    Halsall PJ; Cain PA; Ellis FR
    Br J Anaesth; 1979 Oct; 51(10):949-54. PubMed ID: 518796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occurrence of malignant hyperpyrexia in a patient with osteogenesis imperfecta.
    Rampton AJ; Kelly DA; Shanahan EC; Ingram GS
    Br J Anaesth; 1984 Dec; 56(12):1443-6. PubMed ID: 6498054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Malignant hyperthermia: clinical aspects and treatment (author's transl)].
    Freitag B
    Zentralbl Chir; 1979; 104(6):353-8. PubMed ID: 452750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Muscular enzyme level disorders and a malignant hyperthermia susceptability test: postoperative study of a patient with elevated CPK].
    Perugini M; Montironi C; Rocchi S
    Minerva Anestesiol; 1998; 64(1-2):45-50. PubMed ID: 9658790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
    Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
    Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minor increase of endtidal CO2 during sevoflurane-induced malignant hyperthermia.
    Bonciu M; de la Chapelle A; Delpech H; Depret T; Krivosic-Horber R; Aimé MR
    Paediatr Anaesth; 2007 Feb; 17(2):180-2. PubMed ID: 17238892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative arterial to end-tidal carbon dioxide gradient: an additional sign of malignant hyperthermia during desflurane anesthesia.
    Kwetny I; Finucane BT
    Anesth Analg; 2006 Mar; 102(3):815-7. PubMed ID: 16492834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An automated real-time method for the detection of patients at risk for malignant hyperthermia.
    Gleich SJ; Strupp K; Wilder RT; Kor DJ; Flick R
    Paediatr Anaesth; 2016 Sep; 26(9):876-82. PubMed ID: 27346873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of patients tested for malignant hyperthermia susceptibility.
    Scala D; Di Martino A; Cozzolino S; Mancini A; Bracco A; Andria B; Tammaro A; Savoia G
    Eur J Anaesthesiol; 2006 Sep; 23(9):801-5. PubMed ID: 16780615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ["Malignant hyperthermia" following NLA and spinal anaesthesia (author's transl)].
    Malz H; Gullotta F; Klein H; Aebert K
    Anaesthesist; 1982 May; 31(5):248-51. PubMed ID: 7103033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Malignant hyperthermia--complication of general anesthesia in the clinic of maxillofacial surgery].
    Zavodilenko LA; Bobrinskaia IG; Sluvis VIu
    Anesteziol Reanimatol; 2007; (4):53-6. PubMed ID: 17933043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005.
    Rosero EB; Adesanya AO; Timaran CH; Joshi GP
    Anesthesiology; 2009 Jan; 110(1):89-94. PubMed ID: 19104175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In-vitro-effects of cocaine in skeletal muscle specimens of patients susceptible to malignant hyperthermia].
    Weisshorn R; Wappler F; Fiege M; Gerbershagen M; Schulte Am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Mar; 37(3):138-43. PubMed ID: 11889614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current aspects of the diagnosis of malignant hyperthermia].
    Rüffert H; Olthoff D; Deutrich C; Froster UG
    Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant hyperpyrexia.
    Ellis FR; Halsall PJ
    Br J Hosp Med; 1980 Oct; 24(4):318-21, 323, 325-7. PubMed ID: 7437621
    [No Abstract]   [Full Text] [Related]  

  • 40. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.